Tag Archives: kbio

KaloBios CEO Shkreli Arrested For Securities Fraud

KaloBios Pharmaceuticals (KBIO) CEO Martin Shkreli was arrested on charges of securities fraud Thursday, sending KaloBios stock down more than 50% in premarket before trading was halted. The FBI detained Shkreli on charges that he’d deceived investors in his former hedge fund MSMB Capital Management about the performance of the fund, and paid their supposed returns with funds from Retrophin (RTRX), a biotech company that he headed until the board

KaloBios Up As Much As 5,000% On Shkreli-Led Takeover

Three weeks have made a big difference for KaloBios Pharmaceuticals (KBIO), whose stock since 2014 had fallen into a black hole amid struggles to get a single drug to the market. Meanwhile, AEterna Zentaris (AEZS) doubled Monday as it starts enrollment for a key drug trial. On Nov. 5, KaloBios Pharmaceuticals said it would cut 17 employees from its staff, a 61% reduction. On Nov. 13, the company said it would liquidate its assets and halt

KaloBios, Valeant Lead Week’s 5 Top Drug Stock Gainers

Medical spending tends to rise steadily, but drug stocks can see huge swings as clinical trials, FDA reviews and other news buoy or torpedo the outlook. This week’s 5 big drug winners* rallied for diverse reasons. KaloBios Pharmaceuticals (KBIO) skyrocketed as new buyers stepped in before liquidation. Valeant Pharmaceuticals (VRX) rebounded after a huge sell-off. Sarepta Therapeutics (SRPT) benefited from a rival’s bad news. Voyager Therapeutics